ABR - Abr ABR activator of RhoGEF and GTPase Gene

Species: Rattus norvegicus

Gene Type: protein coding
Gene ID: 287537

Summary

Predicted to enable GTPase activator activity and guanyl-nucleotide exchange factor activity. Predicted to be involved in several processes, including activation of GTPase activity; negative regulation of blood vessel remodeling; and negative regulation of cellular extravasation. Predicted to act upstream of or within several processes, including neuromuscular process controlling balance; regulation of vesicle-mediated transport; and response to lipopolysaccharide. Is active in glutamatergic synapse and postsynaptic density, intracellular component. Orthologous to human ABR (ABR activator of RhoGEF and GTPase). [provided by Alliance of Genome Resources, Apr 2022]

ABR Products (1)

mRNA Protein Name
NM_001105814.4 NP_001099284.1 active breakpoint cluster region-related protein

Gene Ontology

  • Molecular Function
  • Cellular Component
Molecular Function GO Annotation Evidence Références Source
enables protein binding IPI
IPI: Inferred from physical interaction
20962234 RGD
Cellular Component GO Annotation Evidence Références Source
is active in glutamatergic synapse IDA
IDA: Inferred from direct assay
20962234 RGD
is active in postsynaptic density, intracellular component IDA
IDA: Inferred from direct assay
20962234 RGD
EXP: Inferred from Experiment IDA: Inferred from direct assay IPI: Inferred from physical interaction IMP: Inferred from mutant phenotype IGI: Inferred from genetic interaction IEP: Inferred from expression pattern
Protein Preferred Names Protein Names

active breakpoint cluster region-related protein

  • ABR, RhoGEF and GTPase activating protein

  • active BCR-related

  • breakpoint cluster region protein-like

Related Agents

  • Approval
  • Clinical Phase
  • Pre-clinical Phase

Approval

Bioactive Molecules (1)
Cat. No. Nom du produit Effect
Pureté Rare Diseases
HY-13010 Laquinimod 99.46% Yes

Clinical Phase

Bioactive Molecules (5)
Cat. No. Nom du produit Effect
Pureté Phase
HY-10528 Tasquinimod Modulator 99.70% Phase 3
HY-13743 Roquinimex Inhibitor 99.69% Phase 3
HY-W062904 Laquinimod sodium Inhibitor / Phase 3
HY-13743R Roquinimex (Standard) Inhibitor / Phase 3
HY-100442 Paquinimod Inhibitor 99.90% Phase 2

Pre-clinical Phase

Bioactive Molecules (8)
Cat. No. Nom du produit
Effect
Pureté
Rare Diseases
HY-141537 ABR-238901 Inhibitor 98.92% Unkown
HY-100442S1 Paquinimod-d5-1 Inhibitor 98.19% Unkown
HY-10528S Tasquinimod-d3 Modulator 99.34% Unkown
HY-13010S Laquinimod-d5 Inhibitor 98.25% Unkown
HY-RS00110 ABR Human Pre-designed siRNA Set A Pre-designed Set / Unkown
HY-100442S Paquinimod-d5 Inhibitor / Unkown
HY-RS17572 Abr Mouse Pre-designed siRNA Set A Pre-designed Set / Unkown
HY-RS24032 Abr Rat Pre-designed siRNA Set A Pre-designed Set / Unkown
Bioactive MoleculesInhibitory Antibodies (1)
Cat. No. Nom du produit
Effect
Pureté
Rare Diseases
HY-P99436 Anatumomab mafenatox Inhibitor / Unkown

Orthologs Information

Species Symbol Source ID
Homo sapiens ABR NCBI NCBI:29
Macaca fascicularis ABR NCBI NCBI:102126046
Mus musculus ABR NCBI NCBI:109934